Table 1.
Demographics | All | HBsAg-Positive | Resolved HBV | p-Value |
---|---|---|---|---|
N = 118 | N = 55 | N = 63 | ||
Age at diagnosis of SLE (years) | 35.2 ± 14.7 | 37.0 ± 15.2 | 33.6 ± 14.2 | 0.213 |
Female | 97 (82.2) | 44 (80.0) | 53 (84.1) | 0.559 |
Baseline ALT (IU/mL) | 23.4 ± 12.3 | 25.0 ± 12.3 | 22.1 ± 12.2 | 0.200 |
Baseline AST (IU/mL) | 24.7 ± 10.3 | 26.3 ± 10.5 | 23.4 ± 10.0 | 0.125 |
Baseline total bilirubin (mg/dL) | 0.42 ± 0.19 | 0.45 ± 0.19 | 0.40 ± 0.19 | 0.166 |
HBeAg-positive | 10/64 (15.6) | 10/47 (21.3) | 0/17 (0.0) | - |
Anti-HBs positive | 50 (42.4) | 0 (0.0) | 50 (79.4) | - |
Immunologic profiles | ||||
ANA titer > 1:80 | 118 (100.0) | 55 (100.0) | 63 (100.0) | - |
Anti-SSA/Ro positive | 50/94 (53.2) | 17/42 (40.5) | 33/52 (63.5) | 0.026 * |
Anti-SSB/La positive | 17/89 (19.1) | 5/41 (12.2) | 12/48 (25.0) | 0.120 |
Anti-Smith positive | 11/78 (14.1) | 2/39 (5.1) | 9/39 (23.1) | 0.018 * |
Anti-RNP positive | 23/74 (31.1) | 7/36 (19.4) | 16/38 (42.1) | 0.028 * |
Anti-dsDNA positive | 105 (89.0) | 47 (85.5) | 58 (92.1) | 0.252 |
Clinical manifestations | ||||
Hematologic disorder | 81 (68.6) | 34 (61.8) | 47 (74.6) | 0.174 |
Kidney involvement | 49 (41.5) | 20 (36.4) | 29 (46.0) | 0.287 |
CNS involvement | 20 (16.9) | 10 (18.2) | 10 (15.9) | 0.739 |
Psychosis | 4 (3.4) | 2 (3.6) | 2 (3.2) | 0.890 |
Serositis | 13 (11.0) | 7 (12.7) | 6 (14.3) | 0.580 |
Joint involvement | 86 (72.9) | 37 (67.3) | 49 (77.8) | 0.201 |
Skin involvement | 105 (89.0) | 47 (85.5) | 58 (92.1) | 0.252 |
Follow up (years) | 15.4 ± 10.3 | 11.7 ± 9.4 | 18.6 ± 10.2 | <0.001 * |
Abbreviations: ANA, anti-nuclear antibody; anti-HBs, antibody to hepatitis B surface antigen; CNS, central nervous system; dsDNA, double-stranded DNA; HBeAg, hepatitis B virus e antigen; HBsAg, hepatitis B surface antigen; RNP, ribonucleoprotein. Data are presented as frequency (percentage) or mean ± standard deviation. * p < 0.05.